4 results
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
In this pilot-study we investigate the safety, feasibility and efficacy of IRE in locally advanced pancreatic carcinoma. We hypothesize that IRE of the pancreas is a safe treatment that will cause few complications. Moreover, we expect the treatment…
To determine the pharmacokinetic properties of a new elacridar formulation
Primary Objective:To determine whether the addition of eryaspase to chemotherapy improves overall survival (OS) in second-line treatment of pancreatic adenocarcinoma compared to chemotherapy alone.Secondary Objectives:• To compare progression-free…